[
  {
    "ts": "2026-02-13T10:19:53+00:00",
    "headline": "H.C. Wainwright Bullish on ​Genmab A/S (GMAB) on Robust Sales for DARZALEX",
    "summary": "​Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales of DARZALEX in 2025. ​The company on January 21 reported a significant increase in net sales […]",
    "url": "https://finance.yahoo.com/news/h-c-wainwright-bullish-genmab-101953331.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "af7b30e9-184b-35f7-9913-28a9fa9d2b61",
      "content": {
        "id": "af7b30e9-184b-35f7-9913-28a9fa9d2b61",
        "contentType": "STORY",
        "title": "H.C. Wainwright Bullish on ​Genmab A/S (GMAB) on Robust Sales for DARZALEX",
        "description": "",
        "summary": "​Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales of DARZALEX in 2025. ​The company on January 21 reported a significant increase in net sales […]",
        "pubDate": "2026-02-13T10:19:53Z",
        "displayTime": "2026-02-13T10:19:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/92ad993b23d1981cda76510cabc277ab",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V1OWmCXiS8LnmGn5E4BtEQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/92ad993b23d1981cda76510cabc277ab.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FWwGn7BFzbQphqwsKW5kbw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/92ad993b23d1981cda76510cabc277ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-bullish-genmab-101953331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/h-c-wainwright-bullish-genmab-101953331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GNMSF"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:09:38+00:00",
    "headline": "Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study",
    "summary": "Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results […]",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-100-150938116.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1007c48a-6276-38c5-a131-db3919d5074e",
      "content": {
        "id": "1007c48a-6276-38c5-a131-db3919d5074e",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results […]",
        "pubDate": "2026-02-13T15:09:38Z",
        "displayTime": "2026-02-13T15:09:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1i2Xg8sqkYBwxzkIAC02w--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MUHt2SWlA2SDsXLMEXhTeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0de803e1886e8570c453e6c179672b53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-100-150938116.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-100-150938116.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:30+00:00",
    "headline": "Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best medical research stocks to buy according to hedge funds. Johnson & Johnson (NYSE:JNJ) announced 12-month pilot-phase data from the OMNY-AF study on February 6 at the 31st Annual AF Symposium in Boston, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation. It […]",
    "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-one-145730476.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3e8720c6-3d52-3556-9f44-65dd5d1be603",
      "content": {
        "id": "3e8720c6-3d52-3556-9f44-65dd5d1be603",
        "contentType": "STORY",
        "title": "Why is Johnson & Johnson (JNJ) One of the Best Medical Research Stocks to Buy According to Hedge Funds?",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best medical research stocks to buy according to hedge funds. Johnson & Johnson (NYSE:JNJ) announced 12-month pilot-phase data from the OMNY-AF study on February 6 at the 31st Annual AF Symposium in Boston, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation. It […]",
        "pubDate": "2026-02-13T14:57:30Z",
        "displayTime": "2026-02-13T14:57:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-one-145730476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnson-jnj-one-145730476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T19:48:42+00:00",
    "headline": "Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial",
    "summary": "By Diana Novak Jones Feb 13 (Reuters) - A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to",
    "url": "https://finance.yahoo.com/news/pennsylvania-jury-finds-johnson-johnson-194401123.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "bedeb225-03c5-3503-8e35-099b193ac8c4",
      "content": {
        "id": "bedeb225-03c5-3503-8e35-099b193ac8c4",
        "contentType": "STORY",
        "title": "Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial",
        "description": "",
        "summary": "By Diana Novak Jones Feb 13 (Reuters) - A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to",
        "pubDate": "2026-02-13T19:48:42Z",
        "displayTime": "2026-02-13T19:48:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/16bc6fb7913207a5f80a0acc72e57f28",
          "originalWidth": 800,
          "originalHeight": 571,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UmKrxI2b_Zt.PchF.e9FGg--~B/aD01NzE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/16bc6fb7913207a5f80a0acc72e57f28.cf.webp",
              "width": 800,
              "height": 571,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FgzT5IcdmRAThNrkrdCpYw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/16bc6fb7913207a5f80a0acc72e57f28.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pennsylvania-jury-finds-johnson-johnson-194401123.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pennsylvania-jury-finds-johnson-johnson-194401123.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]